Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5604-5612

  Smith, Phillip D ^a,b,f   Shimamura, Masako ^c   Musgrove, Lois C ^a   Dennis, Evida A ^a,c   Bimczok, Diane ^a   Novak, Lea ^d   Ballestas, Mary ^c   Fenton, Anne ^e   Dandekar, Satya ^e   Britt, William J ^c   Smythies, Lesley E ^a,d,f  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; AUTACOID; CYTOKINE;

ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DNA REPLICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL CULTURE; CYTOMEGALOVIRUS INFECTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANTIGENS, CD14; CELLS, CULTURED; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 5; VIRUS REPLICATION;

EID: 84912567324     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302608     Document Type: Article

References (75)

1. Britt, W. 2008. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325: 417-470.
2. Britt, W. J. 2010. Cytomegalovirus. In Infectious Diseases of the Fetus and Newborn Infant, 7th Ed. J. S. Remington, J. O. Klein, C. B. Wilson, V. Nizet, and M. Maldonaldo, eds. Saunders, Philadelphia, p. 706-755.
3. Boppana, S. B., and W. J. Britt. 2013. Synopsis of clinical aspects of human cytomegalovirus disease. In Cytomegaloviruses: From Molecular Pathogenesis to Intervention, 2nd Ed., Vol. II. M. J. Reddehasse, ed. Caister Academic Press, Norfolk, U.K., p. 1-25.
4. Fearon, W. F., L. Potena, A. Hirohata, R. Sakurai, M. Yamasaki, H. Luikart, J. Lee, M. L. Vana, J. P. Cooke, E. S. Mocarski, et al. 2007. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 83: 700-705.
5. Potena, L., F. Grigioni, G. Magnani, T. Lazzarotto, A. C. Musuraca, P. Ortolani, F. Coccolo, F. Fallani, A. Russo, and A. Branzi. 2009. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J. Heart Lung Transplant. 28: 461-467.
6. Nieto, F. J., E. Adam, P. Sorlie, H. Farzadegan, J. L. Melnick, G. W. Comstock, and M. Szklo. 1996. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94: 922-927.
7. Sorlie, P. D., F. J. Nieto, E. Adam, A. R. Folsom, E. Shahar, and M. Massing. 2000. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch. Intern. Med. 160: 2027-2032.
8. Smieja, M., J. Gnarpe, E. Lonn, H. Gnarpe, G. Olsson, Q. Yi, V. Dzavik, M. McQueen, and S. Yusuf, Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. 2003.Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 107: 251-257.
9. Roberts, E. T., M. N. Haan, J. B. Dowd, and A. E. Aiello. 2010. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am. J. Epidemiol. 172: 363-371.
10. Gkrania-Klotsas, E., C. Langenberg, S. J. Sharp, R. Luben, K.-T. Khaw, and N. J. Wareham. 2012. Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J. Infect. Dis. 206: 1897-1903.
11. Kandiel, A., and B. Lashner. 2006. Cytomegalovirus colitis complicating inflammatory bowel disease. Am. J. Gastroenterol. 101: 2857-2865.
12. Domènech, E., R. Vega, I. Ojanguren, A. Hernández, E. Garcia-Planella, I. Bernal, M. Rosinach, J. Boix, E. Cabré, and M. A. Gassull. 2008. Cytomeg-alovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm. Bowel Dis. 14: 1373-1379.
13. Maher, M. M., and M. I. Nassar. 2009. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig. Dis. Sci. 54: 2456-2462.
14. Yi, F., J. Zhao, R. V. Luckheeram, Y. Lei, C. Wang, S. Huang, L. Song, W. Wang, and B. Xia. 2013. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol. J. 10: 43.
15. Park, S. H., S. K. Yang, S. M. Hong, S. K. Park, J. W. Kim, H. J. Lee, D. H. Yang, K. W. Jung, K. J. Kim, B. D. Ye, et al. 2013. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig. Dis. Sci. 58: 3592-3599.
16. Onyeagocha, C., M. S. Hossain, A. Kumar, R. M. Jones, J. Roback, and A. T. Gewirtz. 2009. Latent cytomegalovirus infection exacerbates experimental colitis. Am. J. Pathol. 175: 2034-2042.
17. Matsumura, K., H. Nakase, I. Kosugi, Y. Honzawa, T. Yoshino, M. Matsuura, H. Kawasaki, Y. Arai, T. Iwashita, T. Nagasawa, and T. Chiba. 2013. Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells. Inflamm. Bowel Dis. 19: 1951-1963.
18. Sinclair, J. 2008. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J. Clin. Virol. 41: 180-185.
19. Dankner, W. M., J. A. McCutchan, D. D. Richman, K. Hirata, and S. A. Spector. 1990. Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J. Infect. Dis. 161: 31-36.
20. Taylor-Wiedeman, J., J. G. P. Sissons, L. K. Borysiewicz, and J. H. Sinclair. 1991. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72: 2059-2064.
21. + monocytes. Proc. Natl. Acad. Sci. USA 107: 20039-20044.
22. Sinzger, C., B. Plachter, A. Grefte, T. H. The, and G. Jahn. 1996. Tissue macrophages are infected by human cytomegalovirus in vivo. J. Infect. Dis. 173: 240-245.
23. Smith, P. D., L. E. Smythies, and S. M. Wahl. 2001. Macrophage effector function. In Clinical Immunology, 2nd Ed. R. R. Rich, T. A. Fleisher, W. T. Sherarer, H.W. J. Schroeder, and B. Kotzin, eds. Harcourt Health Sciences, London, p. 19.11-19.19.
24. Smith, M. S., G. L. Bentz, J. S. Alexander, and A. D. Yurochko. 2004. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J. Virol. 78: 4444-4453.
25. Smith, M. S., E. R. Bivins-Smith, A. M. Tilley, G. L. Bentz, G. Chan, J. Minard, and A. D. Yurochko. 2007. Roles of phosphatidylinositol 3-kinase and NF-κB in human cytomegalovirus-mediated monocyte diapedesis and adhesion: strategy for viral persistence. J. Virol. 81: 7683-7694.
26. Reeves, M. B., P. A. MacAry, P. J. Lehner, J. G. Sissons, and J. H. Sinclair. 2005. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl. Acad. Sci. USA 102: 4140-4145.
27. Sinclair, J. 2010. Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection. Biochim. Biophys. Acta 1799: 286-295.
28. Limaye, A. P., K. A. Kirby, G. D. Rubenfeld, W. M. Leisenring, E. M. Bulger, M. J. Neff, N. S. Gibran, M. L. Huang, T. K. Santo Hayes, L. Corey, and M. Boeckh. 2008. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300: 413-422.
29. + + monocytes is differentiation dependent. J. Virol. 75: 7543-7554.
30. Smith, M. S., D. C. Goldman, A. S. Bailey, D. L. Pfaffle, C. N. Kreklywich, D. B. Spencer, F. A. Othieno, D. N. Streblow, J. V. Garcia, W. H. Fleming, and J. A. Nelson. 2010. G-CSF reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe 8: 284-291.
31. von Laer, D., A. Serr, U. Meyer-König, G. Kirste, F. T. Hufert, and O. Haller. 1995. Human cytomegalovirus immediate early and late transcripts are expressed in all major leukocyte populations in vivo. J. Infect. Dis. 172: 365-370.
32. Smythies, L. E., A. Maheshwari, R. Clements, D. Eckhoff, L. Novak, H. L. Vu, L. M. Mosteller-Barnum, M. Sellers, and P. D. Smith. 2006. Mucosal IL-8 and TGF-β recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J. Leukoc. Biol. 80: 492-499.
33. Wynn, T. A., A. Chawla, and J. W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature 496: 445-455.
34. Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115: 66-75.
35. Smith, P. D., S. S. Saini, M. Raffeld, J. F. Manischewitz, and S. M. Wahl. 1992. Cytomegalovirus induction of tumor necrosis factor-a by human monocytes and mucosal macrophages. J. Clin. Invest. 90: 1642-1648.
36. Redman, T. K., W. J. Britt, C. M. Wilcox, M. F. Graham, and P. D. Smith. 2002. Human cytomegalovirus enhances chemokine production by lipopolysaccharidestimulated lamina propria macrophages. J. Infect. Dis. 185: 584-590.
37. Kossmann, T., M. C. Morganti-Kossmann, J. M. Orenstein, W. J. Britt, S. M. Wahl, and P. D. Smith. 2003. Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-β release. J. Infect. Dis. 187: 534-541.
38. Maheshwari, A., L. E. Smythies, X. Wu, L. Novak, R. Clements, D. Eckhoff, A. J. Lazenby, W. J. Britt, and P. D. Smith. 2006. Cytomegalovirus blocks intestinal stroma-induced down-regulation of macrophage HIV-1 infection. J. Leukoc. Biol. 80: 1111-1117.
39. Peterson, P. K., G. Gekker, C. C. Chao, S. X. Hu, C. Edelman, H. H. Balfour, Jr., and J. Verhoef. 1992. Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-a-mediated mechanism. J. Clin. Invest. 89: 574-580.
40. Yurochko, A. D., and E.-S. Huang. 1999. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J. Immunol. 162: 4806-4816.
41. Rubin, R. H., N. E. Tolkoff-Rubin, D. Oliver, T. R. Rota, J. Hamilton, R. F. Betts, R. F. Pass, W. Hillis, W. Szmuness, M. L. Farrell, et al. 1985. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 40: 243-249.
42. Charles, P., F. Ackermann, G. Burdy, O. Blétry, J. Leport, and J. E. Kahn. 2010. Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab. Scand. J. Gastroenterol. 45: 509-510.
43. Bodro, M., N. Sabé, L. Lladó, C. Baliellas, J. Niubó, J. Castellote, J. Fabregat, A. Rafecas, and J. Carratalá. 2012. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl. 18: 1093-1099.
44. Jeon, S., W. K. Lee, Y. Lee, D. G. Lee, and J. W. Lee. 2012. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology 119: 1892-1898.
45. Baek, C. H., W. S. Yang, K. S. Park, D. J. Han, J. B. Park, and S. K. Park. 2012. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra 2: 66-75.
46. Akin, S., F. Tufan, G. Bahat, B. Saka, N. Erten, and M. A. Karan. 2013. Cytomegalovirus esophagitis precipitated with immunosuppression in elderly giant cell arteritis patients. Aging Clin. Exp. Res. 25: 215-218.
47. Smith, I. L., I. Taskintuna, F. M. Rahhal, H. C. Powell, E. Ai, A. J. Mueller, S. A. Spector, and W. R. Freeman. 1998. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 116: 178-185.
48. Britt, W. J., and D. Auger. 1986. Human cytomegalovirus virion-associated protein with kinase activity. J. Virol. 59: 185-188.
49. Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23: 157-167.
50. Shimamura, M., J. E. Murphy-Ullrich, and W. J. Britt. 2010. Human cytomegalovirus induces TGF-β1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition. PLoS Pathog. 6: e1001170.
51. Wahl, L. M., S. M. Wahl, L. E. Smythies, and P. D. Smith. 2006. Isolation of human monocyte populations. Curr. Protoc. Immunol. 7(6A): 1-10.
52. Smythies, L. E., R. Shen, D. Bimczok, L. Novak, R. H. Clements, D. E. Eckhoff, P. Bouchard, M. D. George, W. K. Hu, S. Dandekar, and P. D. Smith. 2010. Inflammation anergy in human intestinal macrophages is due to Smad-induced IkBa expression and NF-κB inactivation. J. Biol. Chem. 285: 19593-19604.
53. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29: e45.
54. Smith, P. D., E. N. Janoff, M. Mosteller-Barnum, M. Merger, J. M. Orenstein, J. F. Kearney, and M. F. Graham. 1997. Isolation and purification of CD14-negative mucosal macrophages from normal human small intestine. J. Immunol. Methods 202: 1-11.
55. Genta, R. M., I. Bleyzer, T. R. Cate, A. K. Tandon, and B. Yoffe. 1993. In situ hybridization and immunohistochemical analysis of cytomegalovirus-associated ileal perforation. Gastroenterology 104: 1822-1827.
56. Bazil, V., and J. L. Strominger. 1991. Shedding as a mechanism of downmodulation of CD14 on stimulated human monocytes. J. Immunol. 147: 1567-1574.
57. Bosshart, H., and M. Heinzelmann. 2011. Spontaneous decrease of CD14 cell surface expression in human peripheral blood monocytes ex vivo. J. Immunol. Methods 368: 80-83.
58. Cohen, L., W. J. Henzel, and P. A. Baeuerle. 1998. IKAP is a scaffold protein of the IkB kinase complex. Nature 395: 292-296.
59. Watters, T. M., E. F. Kenny, and L. A. O'Neill. 2007. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol. Cell Biol. 85: 411-419.
60. Loiarro, M., G. Gallo, N. Fantò, R. De Santis, P. Carminati, V. Ruggiero, and C. Sette. 2009. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J. Biol. Chem. 284: 28093-28103.
61. Lin, S. C., Y. C. Lo, and H. Wu. 2010. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890.
62. Kawagoe, T., S. Sato, K. Matsushita, H. Kato, K. Matsui, Y. Kumagai, T. Saitoh, T. Kawai, O. Takeuchi, and S. Akira. 2008. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat. Immunol. 9: 684-691.
63. Ngo, V. N., R. M. Young, R. Schmitz, S. Jhavar, W. Xiao, K. H. Lim, H. Kohlhammer, W. Xu, Y. Yang, H. Zhao, et al. 2011. Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119.
64. Cheung, A. N. Y., and I. O. Ng. 1993. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am. J. Gastroenterol. 88: 1882-1886.
65. Buckner, F. S., and C. Pomeroy. 1993. Cytomegalovirus disease of the gastrointestinal tract in patients without AIDS. Clin. Infect. Dis. 17: 644-656.
66. Smith, P. D., L. E. Smythies, M. Mosteller-Barnum, D. A. Sibley, M. W. Russell, M. Merger, M. T. Sellers, J. M. Orenstein, T. Shimada, M. F. Graham, and H. Kubagawa. 2001. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol. 167: 2651-2656.
67. Barton, E. S., D. W. White, J. S. Cathelyn, K. A. Brett-McClellan, M. Engle, M. S. Diamond, V. L. Miller, and H. W. Virgin, IV. 2007. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447: 326-329.
68. Yurochko, A. D., E. S. Hwang, L. Rasmussen, S. Keay, L. Pereira, and E. S. Huang. 1997. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-κB during infection. J. Virol. 71: 5051-5059.
69. Yurochko, A. D., M. W. Mayo, E. E. Poma, A. S. Baldwin, Jr., and E. S. Huang. 1997. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-κB promoters. J. Virol. 71: 4638-4648.
70. Jarvis, M. A., J. A. Borton, A. M. Keech, J. Wong, W. J. Britt, B. E. Magun, and J. A. Nelson. 2006. Human cytomegalovirus attenuates interleukin-1β and tumor necrosis factor a proinflammatory signaling by inhibition of NF-κB activation. J. Virol. 80: 5588-5598.
71. Lee, Y. K., H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
72. Zhao, J. Q., L. Z. Chen, J. Qiu, S. C. Yang, L. S. Liu, G. D. Chen, W. Zhang, and Q. Ni. 2011. The role of interleukin-17 in murine cytomegalovirus interstitial pneumonia in mice with skin transplants. Transpl. Int. 24: 845-855.
73. Michelson, S., J. Alcami, S. J. Kim, D. Danielpour, F. Bachelerie, L. Picard, C. Bessia, C. Paya, and J. L. Virelizier. 1994. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor β1. J. Virol. 68: 5730-5737.
74. Yoo, Y. D., C. J. Chiou, K. S. Choi, Y. Yi, S. Michelson, S. Kim, G. S. Hayward, and S. J. Kim. 1996. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor β1 gene through an Egr-1 binding site. J. Virol. 70: 7062-7070.
75. Abraham, C., and J. H. Cho. 2009. Inflammatory bowel disease. N. Engl. J. Med. 361: 2066-2078.